-25% auf alles – bis 31. OktoberKostenloser Versand ab $99 Bestellwert
Chemyo

Verwendung: Dieses Produkt ist ausschließlich für Forschungszwecke bestimmt.

Alle Produktinformationen auf dieser Website dienen ausschließlich Bildungszwecken. Jede Form der Einbringung in den Körper von Menschen oder Tieren ist gesetzlich streng verboten. Dieses Produkt darf nur von zugelassenen und qualifizierten Fachleuten gehandhabt werden. Es ist kein Arzneimittel, Lebensmittel oder Kosmetikum und darf nicht als solches gekennzeichnet, verwendet oder falsch etikettiert werden.

Orforglipron 6mg / 90caps

Orforglipron is a synthetic, non-peptidic GLP-1 receptor agonist studied in controlled research environments for its role in modulating glucagon-like peptide-1 signalling pathways.

Menge
Ursprünglicher Preis war: $198.95Aktueller Preis ist: $149.21.
Bewährte Formel. Neues Design.

Während der Umstellung unserer Verpackung erhalten Sie möglicherweise Produkte mit dem bisherigen oder dem neuen Etikett. Formulierung, Reinheit und Qualität bleiben nach unseren Standards genau gleich.

Akzeptierte Zahlungsmethoden
  • Kreditkarte
  • Banküberweisung (SEPA Echtzeit)
  • Banküberweisung (ACH)
  • Wise
  • Revolut
  • Zelle
  • Remitly
  • Western Union
  • Chime
  • Andere

-25% auf alles – bis 31. Oktober
25% auf reguläre Preise statt anderer Angebote. Nur mit dem Krypto-Zahlungsrabatt kombinierbar.

Versand

Versand am selben Tag für US-Bestellungen vor 12 Uhr EST.

Versandbedingungen ansehen →
Rückgabe

30 Tage unkomplizierte Rückgabe ungeöffneter Produkte.

Rückgabebedingungen ansehen →
Laborgeprüft

Jede Charge wird auf Reinheit, Wirksamkeit und Qualität geprüft.

Laborergebnisse ansehen →
Support

Haben Sie eine Frage? Schreiben Sie uns auf Telegram.

Chat öffnen →

Orforglipron is a synthetic, non-peptidic GLP-1 receptor agonist studied in controlled research environments for its role in modulating glucagon-like peptide-1 signalling pathways. Research focuses on its activity in cAMP-dependent pathways, receptor activation dynamics, and peptide-regulated energy balance mechanisms.

Unlike traditional GLP-1 analogues, Orforglipron demonstrates oral bioactivity and high receptor selectivity, making it suitable for experimental models evaluating small molecule agonists in metabolic signalling systems.

  • High Purity – 99% Purity Guaranteed
  • Independently Lab Tested
  • Research Grade Quality
  • For Laboratory Research Use Only
All Chemyo products are independently third-party tested at a USA-based HPLC-licensed laboratory prior to distribution. Certificates of Analysis (COA) are published on the Independent Test Results page and available at product level. If any independently conducted HPLC test returns a negative result, Chemyo will refund: (1) the cost of the HPLC test, and (2) the full order amount including shipping.
Chemical Formula C48H48F2N10O5
Synonyms LY3502970, OWL833, Foundayo (trade name)
Molar Mass 883.0 g/mol
CAS Number 2212020-52-3
PubChem CID 137319706
Total Compound Content 540 mg (6 mg per capsule)
Shelf Life 36 months
Orforglipron (LY3502970) is a non-peptide small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist developed as a first-in-class orally active GLP-1R modulator. Unlike peptide-based GLP-1R agonists that bind the receptor's extracellular orthosteric peptide-binding domain, Orforglipron interacts with a distinct binding pocket within the transmembrane region of GLP-1R. This unique binding mechanism enables oral bioavailability while maintaining potent receptor activation. In cellular assays, Orforglipron activates Gs-coupled GLP-1R signalling, stimulating adenylate cyclase activity and increasing intracellular cAMP levels with an EC₅₀ of approximately 3 nM. Selectivity over related class B GPCRs, including the GIP receptor, glucagon receptor, and GLP-2 receptor, has been demonstrated in receptor-screening studies. Research applications include GLP-1 receptor pharmacology, allosteric receptor activation mechanisms, non-peptide GPCR agonist development, receptor conformational biology, ligand-binding studies, and comparative analysis of peptide versus small-molecule GLP-1R agonists. The extended elimination half-life of approximately 29–49 hours makes Orforglipron a useful tool for investigating sustained GLP-1R signalling and long-duration receptor activation. Supplied in 6 mg capsules. Independently third-party HPLC-tested; COA available per batch.

Every batch is independently lab tested for identity, purity and potency. View our lab testing program →

How does Orforglipron's binding mechanism differ from peptide GLP-1R agonists?

Peptide GLP-1R agonists interact primarily with the receptor's extracellular peptide-binding domain, whereas Orforglipron binds within the transmembrane region of GLP-1R through a distinct small-molecule binding site. This alternative binding mode stabilizes an active receptor conformation through a mechanism different from endogenous peptide ligands.

As a result, Orforglipron is a valuable research tool for investigating allosteric receptor activation, receptor conformational dynamics, and the differences between peptide-mediated and small-molecule-mediated GLP-1R signalling.

What advantages does Orforglipron provide for GLP-1R pharmacology research?

As an orally active small-molecule agonist, Orforglipron enables investigation of GLP-1R activation without the structural constraints associated with peptide ligands. This makes it useful for studies examining receptor binding-site architecture, signal-transduction mechanisms, receptor trafficking, ligand-specific signalling profiles, and the development of non-peptide class B GPCR agonists.

Its distinct binding mode also allows direct comparison of orthosteric versus non-orthosteric receptor activation mechanisms.

Why is Orforglipron important for studying GLP-1 receptor signalling?

Orforglipron provides a unique platform for exploring how different ligand classes activate the same receptor. Comparative studies can evaluate receptor activation kinetics, cAMP signalling, receptor internalisation, signalling bias, and conformational changes induced by small-molecule versus peptide agonists. These investigations contribute to a broader understanding of GLP-1R pharmacology and class B GPCR activation mechanisms.

Customer Reviews (9)

★★★★★ ★★★★★
4.89 / 5
5★
8
4★
1
3★
0
2★
0
1★
0
★★★★★ ★★★★★
Verified Buyer
Anonymous

US to Us order. Ordered Friday and received following Thursday.

★★★★★ ★★★★★
Verified Buyer
F Grear

Got the products 2 days after my order with free shipping. So far so good.

★★★★★ ★★★★★
Verified Buyer
USA c

Set up coinbase wallet with there directions. Wasn't that hard. Everything they said was on point on shipping.

★★★★★ ★★★★★
Verified Buyer
Mahahind

Extremely nice customer service and helpful. I will highly recommend it to my friends.Great product.

★★★★★ ★★★★★
Verified Buyer
James

Incredibly fast shipping and the product met all my expectations. A seamless experience from start to finish.